Skye Bioscience, Inc. ( (SKYE) ) has released its Q2 earnings. Here is a breakdown of the information Skye Bioscience, Inc. presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on developing innovative molecules that modulate G-protein-coupled receptors to address obesity, overweight, and related conditions. The company recently released its second-quarter 2025 financial results and provided a business update, highlighting progress in its CBeyond™ Phase 2a study of nimacimab, a promising treatment for obesity.
In the latest quarter, Skye Bioscience reported significant advancements in its clinical trials, including the initiation of patient enrollment for the extension study of its Phase 2a obesity trial. The study has shown promising results, with nimacimab demonstrating superior weight rebound profiles compared to incretin therapies in preclinical studies. Additionally, the company successfully manufactured and released its first batch of nimacimab for the ongoing trial.
Financially, Skye Bioscience reported a net loss of $17.6 million for the quarter, primarily due to increased research and development expenses associated with its nimacimab clinical study. Despite the losses, the company maintains a strong cash position, with $48.6 million in cash, cash equivalents, and short-term investments, expected to support operations through at least the first quarter of 2027.
Looking ahead, Skye Bioscience remains optimistic about nimacimab’s potential as a monotherapy or in combination with other treatments, aiming to redefine obesity care with its unique mechanism. The company anticipates sharing more insights during upcoming events and continues to focus on advancing its clinical trials and strategic initiatives.